Latest From Biotech Now
October is Get to Know GMOs Month, and GMO Answers is bringing you information about biotechnology in agriculture. In week one we discussed the biggest misconceptions about GMOs, followed by week where we covered GMO basics. In week three, we talked about the science of GMOs. Now in our final week, GMO Answers has reached out to the people who study and grow GMOs to share their perspectives with you. The People Who Grow GMOs Watch the video below of Read More >
As of October 23,2014 more than 4,900 people have died from the current Ebola outbreak, concentrated in the three West African countries of Sierra Leone, Guinea, and Liberia. Frustrated that the process of getting experimental vaccines to West Africa was not moving fast enough, some were quick to blame intellectual property rights. But in reality, as government officials were quick to point out, the WHO first needed to resolve important ethical and safety considerations before a vaccine that Read More >
Amid the cacophony of calls for patent reform legislation, mounting evidence demonstrates patent trolling may be on the wane. As we reported earlier this month, the number of new patent cases filed in federal court has dropped by an astonishing 40 percent as compared to this time last year. A new data analysis by Unified Patents data shows more signs that patent troll suits are in decline.
Lung cancer is the leading cause of cancer death in the US, taking the lives of twice as many women as breast cancer and three times as many men as prostate cancer. While a history of smoking is the main risk factor for developing lung cancer, nearly 80% of those diagnosed today were never smokers or are former smokers who quit decades ago. November is Lung Cancer Awareness Month, a time of reflection for advocates Read More >
Earlier this week, John Fauber of the Milwaukee Journal Sentinel wrote an article on measures used to determine whether new medicines for serious and life-threatening diseases should reach patients. Fauber seem(s) to suggest that the use of surrogate measures – such as tumor shrinkage – do not provide evidence of drug efficacy. The story fails to present a balanced view of the complex benefit-risk assessments that the FDA must carefully consider when reviewing applications for Read More >